Treatment of colorectal cancer (CRC) is mainly surgical and involves removal of the affected bowel section. Prevention of post-surgical complications needs the development of a new biomaterial.
CRC is the second most common form of cancer and the third most common cause of death from cancer in Europe. At least 50 % of the western population develop some form of CRC by the age of 70, spanning the spectrum from an early benign polyp to an invasive adenocarcinoma.
Further information: Prevention of bowel surgery complications